Can oral nonsteroidal antiinflammatory drugs play a role in the prevention of basal cell carcinoma? A systematic review and metaanalysis - 18/12/15
Abstract |
Background |
Evidence for an association between aspirin or other nonsteroidal antiinflammatory drug (NSAID) use and basal cell carcinoma (BCC) has been inconsistent.
Objective |
We conducted a systematic review and metaanalysis to assess the effect of oral NSAIDs on BCC.
Methods |
PubMed, Web of Science, and Embase databases were searched up to December 3, 2014. A random effects model metaanalysis was used to calculate summary estimates of the effects of aspirin, nonaspirin NSAIDs, or any (aspirin or nonaspirin) NSAID use in patients with BCC.
Results |
The summary estimates from 11 studies (1 randomized controlled trial, 5 cohort studies, and 5 case control studies) found a 10% risk reduction of BCC among those using any NSAID (relative risk [RR], 0.90 [95% confidence interval {CI}, 0.84-0.97]). A similar but not statistically significant inverse association was observed for nonaspirin NSAIDs (RR, 0.93 [95% CI, 0.86-1.02]), while aspirin use was more weakly associated (RR, 0.95 [95% CI, 0.91-1.00]). The strongest inverse associations were noted among those with either a history of skin cancers or a high prevalence of actinic keratoses.
Limitations |
Dose-effect estimates could not be calculated because the available data were too heterogeneous to pool.
Conclusion |
The intake of NSAIDs may help prevent BCC, particularly in high-risk populations. A large randomized controlled trial is required to confirm these findings.
Le texte complet de cet article est disponible en PDF.Key words : aspirin, basal cell carcinoma, metaanalysis, NSAIDs, skin cancer, systematic review
Abbreviations used : BCC, CI, COX, NSAID, OR, RCT
Plan
Supported by Program Grant 552429 from the National Health and Medical Research Council of Australia (Dr Olsen) and a postdoctoral fellowship of The University of Queensland (Dr Pandeya). |
|
Conflicts of interest: None declared. |
Vol 74 - N° 1
P. 108 - janvier 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?